{
    "65cfae831930410b13000015":
    {
        "question": "What is the use of P85-Ab?",
        "llm_evidence": "P85-Ab, or P85 antibody, is primarily used in research and clinical diagnostics to study the activity of the phosphoinositide 3-kinase (PI3K) pathway. This antibody targets the p85 regulatory subunit of PI3K, which plays a crucial role in mediating downstream signaling in response to various growth factors and hormones. Key insights into its use include:\n\n1. **Cancer Research**: P85-Ab is pivotal in understanding cancer biology, as the PI3K pathway is frequently dysregulated in various cancers, impacting cell proliferation and survival.\n\n2. **Metabolism Studies**: The antibody helps in studying metabolic diseases, where PI3K signaling is involved in insulin signaling and glucose metabolism.\n\n3. **Immunological Applications**: P85-Ab is also utilized in immunology to explore immune cell signaling, contributing to the understanding of autoimmune diseases.\n\n4. **Drug Development**: Researchers use P85-Ab in assays to evaluate the effectiveness of PI3K inhibitors, which are being developed as targeted therapies in oncology and other diseases.\n\nThese applications illustrate the versatility of P85-Ab as a significant tool in both basic research and clinical studies, allowing scientists to unravel the complexities of the PI3K signaling pathway."
    },
    "662fc44b187cba990d000015":
    {
        "question": "What are the indicated prophylaxis treatments for acute cholinergic syndrome secondary to irinotecan?",
        "llm_evidence": "Acute cholinergic syndrome can occur as a side effect of irinotecan, primarily due to the drug's metabolite, SN-38, which inhibits acetylcholinesterase activity, leading to increased acetylcholine levels. Prophylactic treatments indicated for managing this syndrome include the administration of anticholinergic agents such as atropine or scopolamine, which help counteract the excess acetylcholine. Additionally, patients may benefit from the use of prophylactic doses of loperamide to mitigate diarrhea, a common side effect associated with irinotecan. Regular monitoring and supportive care are also essential to manage symptoms effectively and prevent severe complications related to cholinergic toxicity."
    },
    "662cf81b187cba990d000001":
    {
        "question": "What is the function of FAM134B (also called JK-1, RETREG1)?",
        "llm_evidence": "FAM134B, also known as JK-1 or RETREG1, is a protein that plays a crucial role in the process of selective autophagy, specifically in the degradation of misfolded proteins in the endoplasmic reticulum (ER). It functions as an ER-resident receptor that facilitates the sequestration and delivery of these proteins to autophagosomes for lysosomal degradation, a process essential for maintaining cellular homeostasis. \n\nKey insights include:\n\n1. **ER Stress Response**: FAM134B is activated during ER stress, helping to clear dysfunctional proteins, which is vital for cell survival and function.\n2. **Role in Diseases**: Mutations or downregulation of FAM134B have been linked to various diseases, including cancer and neurodegenerative disorders, emphasizing its importance in cellular health.\n3. **Interaction with Other Proteins**: FAM134B interacts with several proteins involved in the autophagy pathway, enhancing the efficiency of the autophagic process.\n\nIn summary, FAM134B functions primarily as a receptor that mediates the selective degradation of misfolded proteins through autophagy, playing a significant role in maintaining cellular function and responding to stress."
    },
    "661688cefdcbea915f000053":
    {
        "question": "What cancers are associated with human papilloma virus?",
        "llm_evidence": "Human papillomavirus (HPV) is a significant risk factor for several types of cancer, most notably cervical cancer. Approximately 70% of cervical cancer cases are linked to HPV infections, particularly strains 16 and 18. In addition to cervical cancer, HPV is also associated with other anogenital cancers, including vulvar, vaginal, penile, and anal cancers. Furthermore, oropharyngeal cancers, particularly those affecting the base of the tongue and tonsils, have increasingly been linked to HPV, especially strain 16. Vaccination against HPV can significantly reduce the incidence of these cancers by preventing the transmission of high-risk HPV strains. Key insights reveal that HPV’s role as a carcinogen underscores the importance of vaccination and screening programs for effective cancer prevention."
    },
    "662fdb1e187cba990d000019":
    {
        "question": "What is the role of the transcription factor activator protein 2 (AP-2) alpha (TFAP2A) in tumor formation and metastasis?",
        "llm_evidence": "Transcription factor activator protein 2 alpha (TFAP2A) plays a multifaceted role in tumor formation and metastasis. Its function as a transcriptional regulator significantly influences cellular processes associated with cancer progression. Key insights include:\n\n1. **Tumor Suppressor and Oncogene Roles**: TFAP2A can function as a tumor suppressor in certain contexts, inhibiting cell proliferation and promoting apoptosis. Conversely, in other scenarios, it may act as an oncogene, particularly in specific types of cancers, such as breast and colorectal cancers, where it can enhance tumor growth.\n\n2. **Regulation of Key Genes**: TFAP2A regulates the expression of genes involved in cell adhesion, migration, and invasion. By modulating cell-cell interactions and extracellular matrix components, it promotes metastatic potential, contributing to tumor spread.\n\n3. **Interaction with Signaling Pathways**: It interacts with various signaling pathways, including the Wnt and MAPK pathways, to influence cancer cell behavior. These interactions can promote epithelial-mesenchymal transition (EMT), a crucial step in metastasis.\n\n4. **Influence on Tumor Microenvironment**: TFAP2A may affect the tumor microenvironment by regulating immune responses and the behavior of stromal cells, thereby facilitating tumor growth and dissemination.\n\n5. **Prognostic Marker**: Elevated levels of TFAP2A expression in tumors are often associated with poor prognosis, highlighting its potential as a biomarker for cancer aggressiveness and metastatic potential.\n\nIn summary, TFAP2A is a critical player in the complex web of transcriptional regulation that governs tumor formation and metastasis, alternating between promoting and inhibiting roles depending on the cancer type and context."
    },
    "66300f53187cba990d00001d":
    {
        "question": "Which vaccines are safe to be administered for all pregnancies?",
        "llm_evidence": "During pregnancy, certain vaccines are recommended for safe administration to protect both the mother and the fetus. Key vaccines include:\n\n1. **Inactivated Influenza Vaccine (IIV)**: Pregnant individuals are at higher risk for severe illness from influenza; thus, the flu vaccine is recommended during any trimester.\n\n2. **Tdap Vaccine**: The tetanus, diphtheria, and pertussis (Tdap) vaccine is recommended during each pregnancy, preferably between 27 and 36 weeks of gestation, to protect newborns from whooping cough.\n\n3. **COVID-19 Vaccines**: Current evidence supports the safety and efficacy of COVID-19 vaccines during pregnancy, helping to protect both the mother and the baby from severe COVID-19 outcomes.\n\nThese vaccines are considered safe and crucial for preventing serious infectious diseases during pregnancy, contributing to better health outcomes for both mothers and infants. It's always recommended that pregnant individuals consult with their healthcare provider for personalized advice and to stay updated with the latest guidelines."
    },
    "65d36e761930410b13000044":
    {
        "question": "What is the use of lebrikizumab?",
        "llm_evidence": "Lebrikizumab is a monoclonal antibody that targets interleukin-13 (IL-13), which plays a key role in inflammatory processes, particularly in atopic dermatitis (AD) and other allergic conditions. It has been developed primarily for the treatment of moderate to severe AD in adults and adolescents who are candidates for systemic therapy. Clinical trials have demonstrated that lebrikizumab significantly improves skin clearance, overall disease severity, and quality of life for patients suffering from AD. By inhibiting IL-13, it helps reduce inflammation and alleviate symptoms associated with this chronic skin condition. Additionally, lebrikizumab may be investigated for potential use in other inflammatory diseases, emphasizing its role as an effective therapeutic agent in managing conditions driven by IL-13."
    },
    "662fc981187cba990d000018":
    {
        "question": "Is CT colonography a cost-effective test for colorectal cancer screening?",
        "llm_evidence": "CT colonography, also known as virtual colonoscopy, has shown to be a cost-effective alternative for colorectal cancer screening, especially for patients who are reluctant to undergo traditional colonoscopy. Key insights supporting this include:\n\n1. **Sensitivity and Specificity:** Studies indicate that CT colonography is highly sensitive for detecting colorectal cancer and significant polyps, making it an effective screening tool.\n\n2. **Non-Invasiveness:** Unlike traditional colonoscopy, CT colonography is non-invasive and does not require sedation, leading to lower associated costs and facilitating more patients to get screened.\n\n3. **Higher Compliance Rates:** Due to its less invasive nature, CT colonography tends to attract more individuals to screening programs, potentially increasing early detection rates and ultimately lowering treatment costs by catching cancer at earlier stages.\n\n4. **Cost-Effectiveness Analyses:** Economic evaluations comparing CT colonography to other screening modalities, such as traditional colonoscopy and fecal immunochemical testing, suggest that CT colonography can reduce overall healthcare costs when considering factors like procedure costs, complications, and follow-up diagnostics.\n\n5. **Guideline Endorsements:** Organizations like the American College of Radiology and the US Multi-Society Task Force on Colorectal Cancer have endorsed CT colonography as an acceptable screening method, further supporting its viability.\n\nOverall, the combination of high diagnostic performance, enhanced patient compliance, and favorable cost analyses underscores CT colonography as a cost-effective option for colorectal cancer screening."
    },
    "662cf888187cba990d000002":
    {
        "question": "is Cryoglobulinemic vasculitis (CV), also known as mixed cryoglobulinemic syndrome (MCS), a systemic vasculitis that affects large blood vessels.",
        "llm_evidence": "Cryoglobulinemic vasculitis (CV), or mixed cryoglobulinemic syndrome (MCS), is primarily characterized as a type of small to medium vessel vasculitis rather than a systemic vasculitis affecting large blood vessels. It arises from the presence of cryoglobulins in the blood, which are immunoglobulins that precipitate at cooler temperatures and can cause inflammation and damage to blood vessels, typically affecting the skin, kidneys, and nervous system. The most common forms of CV are associated with chronic infections (especially hepatitis C), autoimmune diseases, and certain malignancies. Key insights include:\n\n1. **Vessel Size Specificity**: CV mainly impacts small to medium-sized blood vessels, leading to manifestations such as purpura, renal injury, and neuropathy, rather than involving larger vessels.\n\n2. **Clinical Features**: Symptoms often include skin lesions (such as palpable purpura), arthralgia, and systemic symptoms due to the organ effects of inflammation in these smaller vessels.\n\n3. **Diagnosis and Histopathology**: The diagnosis typically involves serological tests for cryoglobulins, along with skin or kidney biopsies where small vessel inflammation is noted.\n\nIn summary, while CV is a serious condition affecting multiple systems, it does not primarily involve large blood vessels, distinguishing it from other systemic vasculitides like giant cell arteritis or polyarteritis nodosa."
    },
    "66155e7dfdcbea915f00004c":
    {
        "question": "Consequences for the newborn of infection by Zika virus during pregnancy.",
        "llm_evidence": "Infection with the Zika virus during pregnancy can have severe consequences for the newborn, primarily leading to congenital Zika syndrome (CZS). Key insights include:\n\n1. **Microcephaly**: One of the most significant outcomes is microcephaly, a condition where the baby is born with an abnormally small head, which can result in developmental delays and neurological issues.\n\n2. **Brain Development Issues**: In addition to microcephaly, Zika infection may cause other brain malformations, such as calcifications and abnormalities in brain structure, leading to cognitive and motor impairments.\n\n3. **Eye Defects**: Infants may also present with visual impairment, including optic nerve damage and retinal defects, which can affect their ability to interact with their environment.\n\n4. **Hearing Loss**: Zika infection can result in neurological damage that may lead to hearing problems or loss in affected infants.\n\n5. **Other Complications**: Beyond CZS, Zika virus infection can contribute to other issues such as growth restrictions and developmental delays, impacting motor skills and learning abilities as the child grows.\n\n6. **Long-term Effects**: Many of these conditions can lead to lifelong disabilities, requiring early intervention and ongoing support for families.\n\nOverall, the consequences of Zika virus infection during pregnancy underscore the critical need for preventive measures and monitoring of pregnant individuals in affected regions."
    },
    "66302090187cba990d00002a":
    {
        "question": "Which are the key transcription factors known to drive glioma progression and therapy resistance?",
        "llm_evidence": "Key transcription factors that drive glioma progression and therapy resistance include:\n\n1. **NF-κB (Nuclear Factor kappa-light-chain-enhancer of activated B cells)**: This transcription factor is involved in cell survival, proliferation, and inflammation and has been shown to contribute to glioma aggressiveness and the evasion of apoptosis, leading to resistance against therapies such as radiation and chemotherapy.\n\n2. **STAT3 (Signal Transducer and Activator of Transcription 3)**: Activated by various growth factors and cytokines, STAT3 promotes glioma cell proliferation, survival, and invasion. Its persistent activation is associated with poor prognosis and resistance to treatments, including targeted therapies.\n\n3. **HIF-1α (Hypoxia-Inducible Factor 1-alpha)**: In the hypoxic tumor microenvironment of gliomas, HIF-1α is upregulated, promoting angiogenesis and metabolic adaptation. This adaptation not only facilitates tumor growth but also contributes to resistance against therapies by enabling tumor cells to survive under low oxygen conditions.\n\n4. **OCT4 (Octamer-binding transcription factor 4)**: Often associated with stem cell properties, OCT4 is linked to glioma stem cells, which are thought to play a crucial role in tumor initiation and recurrence. Its expression is associated with therapy resistance and the ability to sustain tumor growth post-treatment.\n\n5. **SOX2 (SRY-Box Transcription Factor 2)**: Similar to OCT4, SOX2 is implicated in maintaining stemness in gliomas. Its expression correlates with increased tumor aggressiveness and poor therapeutic responses, as it supports the self-renewal and multipotent characteristics of glioma stem cells.\n\nThese transcription factors are intertwined in pathways that promote glioma progression and enable tumor cells to resist various therapeutic modalities, making them important targets for research and potential therapeutic intervention."
    },
    "662e29f9187cba990d00000a":
    {
        "question": "What are the genotypes of Japanese Encephalitis Virus (JEV)?",
        "llm_evidence": "Japanese Encephalitis Virus (JEV) is classified into several genotypes based on genetic sequencing studies. The primary genotypes include:\n\n1. **Genotype I (GI)**: This is the most widely distributed genotype and is commonly found in Asia, particularly in Japan, Korea, and parts of Southeast Asia. It is associated with the large-scale outbreaks of JEV.\n\n2. **Genotype II (GII)**: Primarily identified in the South Pacific region, including in islands such as the Solomon Islands and more recently in China. This genotype has shown a limited geographical distribution compared to GI.\n\n3. **Genotype III (GIII)**: Found mostly in Southeast Asia and known to be responsible for sporadic outbreaks.\n\n4. **Genotype IV (GIV)**: More recently recognized, primarily reported in the Bangladesh region.\n\nIn addition to these genotypes, there is also ongoing research into new variants and their epidemiological implications. Genetic diversity within these genotypes can influence the virulence and transmissibility of the virus, highlighting the importance of continuous monitoring to manage and prevent Japanese Encephalitis outbreaks."
    },
    "65d373151930410b13000048":
    {
        "question": "What medication were tested in the TRICOTEL trial?",
        "llm_evidence": "The TRICOTEL trial investigated the efficacy of combined treatments involving T-cell engaging bispecific antibodies, specifically targeting CD3 and CD19, in patients with B-cell malignancies. The trial aimed to evaluate the safety and effectiveness of these bispecific antibodies in conjunction with standard therapeutic agents. By focusing on personalized medicine approaches, the TRICOTEL trial contributes valuable insights into innovative treatment options for patients with complex hematological conditions."
    },
    "66214ff0b9f8b89d7e000006":
    {
        "question": "What are the most frequent side effects of regorafenib?",
        "llm_evidence": "Regorafenib, an oral multikinase inhibitor used primarily for metastatic colorectal cancer and gastrointestinal stromal tumors, is associated with several common side effects. The most frequent adverse effects include:\n\n1. **Fatigue**: Many patients experience a significant level of tiredness and general malaise, impacting their daily activities.\n   \n2. **Diarrhea**: Regorafenib can cause gastrointestinal disturbances, leading to frequent episodes of diarrhea, which may sometimes be severe.\n\n3. **Hypertension**: An increase in blood pressure is commonly observed and requires monitoring and management during treatment.\n   \n4. **Hand-foot skin reaction**: Patients often report skin issues such as redness, swelling, and pain on the palms of the hands and soles of the feet.\n\n5. **Nausea**: Many individuals experience nausea, which can range from mild to severe, sometimes necessitating treatment adjustments.\n\n6. **Alopecia**: Hair loss or thinning is reported by a number of patients undergoing therapy with regorafenib.\n\nThese side effects can significantly impact the patients' quality of life and may require supportive care or dose adjustments. Monitoring and proactive management of these effects are essential to maintain treatment adherence and overall well-being."
    },
    "662cf8db187cba990d000003":
    {
        "question": "Is Periostin a novel biomarker of TH2-driven asthma?",
        "llm_evidence": "Periostin has emerged as a promising biomarker specifically associated with TH2-driven asthma. It is an extracellular matrix protein that is upregulated in response to IL-4 and IL-13, key cytokines involved in TH2 immune responses. Elevated levels of periostin in the airway, serum, and sputum have been correlated with eosinophilic inflammation and airway hyperresponsiveness, which are hallmark features of TH2-driven asthma. Clinical studies have demonstrated that periostin levels can predict the severity of asthma symptoms and the response to corticosteroid treatment. Additionally, periostin has been linked to changes in lung function and may serve as a potential therapeutic target. These insights collectively support the role of periostin as a novel biomarker in identifying and managing TH2-driven asthma."
    },
    "66168a89fdcbea915f000054":
    {
        "question": "Burkitt lymphoma and Epstein-Barr virus.",
        "llm_evidence": "Burkitt lymphoma is a highly aggressive type of non-Hodgkin lymphoma characterized by the proliferation of B-cells. A substantial body of evidence links Burkitt lymphoma to the Epstein-Barr virus (EBV), a member of the herpesvirus family. EBV is known to infect B-cells, and its association with Burkitt lymphoma is particularly evident in endemic forms, primarily observed in sub-Saharan Africa, where the infection rates are high. Studies show that nearly 95% of endemic Burkitt lymphoma cases harbor EBV, with the virus playing a crucial role in the oncogenic process.\n\nEBV contributes to the tumorigenesis of Burkitt lymphoma through mechanisms such as the expression of latent viral proteins, which can promote cell proliferation and inhibit apoptosis. In non-endemic cases, while the association with EBV is less prevalent, about 15-20% of these cases still demonstrate EBV involvement. The presence of EBV in Burkitt lymphoma provides insights into potential therapeutic targets and the importance of monitoring EBV infection in high-risk populations. Overall, the evidence strongly establishes a significant relationship between Burkitt lymphoma and EBV, underscoring the virus's role in the pathogenesis of this aggressive lymphoma."
    },
    "663020de187cba990d00002c":
    {
        "question": "What tumor suppressor genes are commonly affected by glioblastoma mutations or deletions?",
        "llm_evidence": "Glioblastoma, a highly aggressive brain tumor, frequently involves alterations in several key tumor suppressor genes. The most commonly affected are:\n\n1. **TP53**: Mutations in the TP53 gene, which encodes the p53 protein, are prevalent in glioblastomas. p53 is crucial for regulating the cell cycle and apoptosis, and its dysfunction can lead to uncontrolled cellular proliferation.\n\n2. **NF1**: The neurofibromatosis type 1 gene (NF1) is often mutated or deleted in glioblastoma. NF1 encodes a protein that negatively regulates the RAS pathway, and loss of NF1 function can result in enhanced cell growth and survival.\n\n3. **PTEN**: The phosphatase and tensin homolog (PTEN) gene is another critical tumor suppressor affected in glioblastoma. PTEN normally inhibits the PI3K/AKT signaling pathway, and its loss leads to increased cell metabolism, survival, and growth.\n\n4. **CDKN2A**: Deletions or mutations in the CDKN2A gene, which encodes p16INK4a, are common in glioblastoma. This protein is involved in cell cycle regulation, and its loss removes a critical checkpoint, allowing for unchecked cellular division.\n\nThese genetic alterations contribute significantly to glioblastoma's aggressive nature, promoting tumor growth, survival, and resistance to treatment."
    },
    "6630211d187cba990d00002d":
    {
        "question": "Is there an association between specific genotypes and the risk of ASD for Duchenne Muscular Dystrophy?",
        "llm_evidence": "Duchenne Muscular Dystrophy (DMD) is primarily caused by mutations in the dystrophin gene, which not only affects muscle function but can also impact cognitive and behavioral outcomes. Research indicates that individuals with DMD are at a higher risk for Autism Spectrum Disorder (ASD). Studies have shown that specific genotypes associated with DMD, particularly mutations in dystrophin, can lead to neurodevelopmental abnormalities. \n\nKey insights include:\n\n1. **Genetic Overlap**: Both DMD and ASD share certain genetic risk factors, suggesting that mutations in the dystrophin gene may have a broader effect on brain development and behavior.\n\n2. **Neurobiological Mechanisms**: Dystrophin plays a role in neuronal function and synaptic stability, and its absence due to mutations may contribute to the development of autism-like behaviors.\n\n3. **Epidemiological Findings**: Numerous epidemiological studies have found a higher prevalence of ASD in boys with DMD compared to the general population, indicating a strong association between specific genotypes related to DMD and the risk of developing ASD.\n\n4. **Therapeutic Considerations**: Understanding the genetic mechanisms linking DMD and ASD may pave the way for targeted therapies that address both muscle function and behavioral symptoms in affected individuals.\n\nOverall, the evidence supports a notable association between specific genotypes related to DMD and an increased risk of ASD, highlighting the complex interplay between genetic mutations and neurodevelopmental outcomes."
    },
    "65d144b81930410b13000041":
    {
        "question": "Coffee Bean Sign is characteristic to which disease?",
        "llm_evidence": "Coffee Bean Sign is characteristic of **Bowel Obstruction**. This radiographic finding is noted on X-rays as elongated, air-filled structures that resemble coffee beans and is associated with the presence of dilated bowel loops. The \"coffee bean\" appearance is typically indicative of a sigmoid volvulus, a condition where a portion of the colon twists upon itself, leading to obstruction. Prompt diagnosis and intervention are crucial to prevent severe complications such as bowel ischemia or perforation."
    },
    "662fc351187cba990d000014":
    {
        "question": "What role does epiregulin and amphiregulin play in the use of EGFR inhibitors for colorectal cancer?",
        "llm_evidence": "Epiregulin and amphiregulin are both ligands for the epidermal growth factor receptor (EGFR), playing critical roles in cellular signaling and tumor biology. In the context of colorectal cancer, their expression levels can impact the efficacy of EGFR inhibitors, such as cetuximab and panitumumab. \n\nKey insights include:\n\n1. **Ligand Dependency**: High levels of epiregulin and amphiregulin can lead to ligand-driven activation of EGFR, even in cases where the receptor is targeted by inhibitors. This activation may diminish the therapeutic effects of EGFR inhibitors.\n\n2. **Predictive Biomarkers**: The presence of these ligands has been investigated as potential biomarkers for predicting response to EGFR-targeted therapies. Elevated plasma levels of epiregulin and amphiregulin may correlate with resistance to treatment, suggesting that their assessment could inform patient selection for EGFR inhibitors.\n\n3. **Co-regulation with Other Pathways**: Both ligands can interact with other signaling pathways, including the HER family of receptors, which might contribute to cancer aggressiveness and treatment resistance. Understanding their interplay with these pathways may help identify combination strategies that enhance treatment efficacy.\n\nIn summary, epiregulin and amphiregulin not only serve as important players in EGFR signaling but also hold potential as biomarkers for resistance to EGFR inhibitors in colorectal cancer, impacting treatment outcomes."
    },
    "662cfc88187cba990d000008":
    {
        "question": "What process does tRNA nucleotidyl transferase 1 (TRNT1)  catalyze?",
        "llm_evidence": "tRNA nucleotidyl transferase 1 (TRNT1) catalyzes the addition of the 3' terminal nucleotide to tRNA molecules during their post-transcriptional modification. This enzyme is crucial for the maturation of tRNA by facilitating the addition of a single nucleoside to the free hydroxyl group at the 3' end of the tRNA molecule, resulting in the conversion of precursor tRNA to functional tRNA. TRNT1 is involved in ensuring the stability and proper function of tRNA, thereby playing a vital role in the overall protein synthesis process. Dysregulation of TRNT1 activity can lead to defects in tRNA processing, which may disrupt protein translation and contribute to various diseases."
    },
    "6614f810fdcbea915f000043":
    {
        "question": "What are the causes for heart and lung transplantation in children?",
        "llm_evidence": "Heart and lung transplantation in children are primarily driven by severe, life-threatening conditions that compromise organ function and overall health. Key causes include:\n\n1. **Congenital Heart Defects**: Many children are born with structural heart abnormalities that can lead to heart failure. Common conditions include tetralogy of Fallot, hypoplastic left heart syndrome, and transposition of the great arteries.\n\n2. **Cardiomyopathy**: This condition, characterized by the heart muscle becoming enlarged, thickened, or rigid, can be hereditary or acquired. Dilated cardiomyopathy tends to be the most common type in children, often leading to heart failure.\n\n3. **End-Stage Heart Disease**: Conditions such as myocarditis (inflammation of the heart muscle) or chronic arrhythmias, which can be idiopathic or due to secondary causes, may result in irreversible heart failure necessitating transplantation.\n\n4. **Lung Diseases**: In children, primary pulmonary hypertension, cystic fibrosis, and other chronic lung conditions may lead to respiratory failure and the need for a lung transplant.\n\n5. **Pulmonary Vascular Disease**: This includes conditions affecting blood vessels in the lungs, such as those caused by congenital anomalies or chronic respiratory diseases, leading to end-stage lung disease.\n\nThese factors collectively necessitate heart and lung transplants when medical management is no longer effective and the child is at high risk for mortality."
    },
    "662edc6f187cba990d00000c":
    {
        "question": "Can enhancer-promoter interactions form independently of genomic distance?",
        "llm_evidence": "Enhancer-promoter interactions can indeed form independently of genomic distance, as evidenced by several studies demonstrating that enhancers can influence promoters that are located thousands of base pairs away as well as those in close proximity. Key insights include:\n\n1. **Chromatin Architecture**: The three-dimensional organization of the genome allows enhancers to loop around and contact promoters, facilitating gene expression regardless of linear distance. Techniques such as Hi-C have proven that interactions often occur over long distances within the nuclear space.\n\n2. **Transcription Factor Dynamics**: Enhancers are bound by transcription factors that can traverse significant distances in the nucleus. These factors can mediate the formation of complexes with RNA polymerase II at promoters, showing that physical separation in the linear sequence does not preclude functional interaction.\n\n3. **Regulatory Mechanisms**: Some enhancers function autonomously and can be activated by specific signals that do not rely on proximity to their target promoter. This supports the idea that the regulatory influence of enhancers is more a product of their specific sequence and binding interactions than their genomic location.\n\nOverall, while proximity may enhance the efficiency of communication between enhancers and promoters, evidence indicates that functional interactions can occur across significant genomic distances."
    },
    "66300d3e187cba990d00001b":
    {
        "question": "What is the prevalence of intellectual developmental disorders in Becker Muscular Dystrophy?",
        "llm_evidence": "Becker Muscular Dystrophy (BMD) is primarily characterized by muscle weakness and degeneration, but it can also be associated with cognitive impairments. While not all individuals with BMD exhibit intellectual developmental disorders, studies indicate a prevalence ranging from 20% to 35% of patients showing varying degrees of cognitive deficits, especially in areas such as verbal intelligence and executive function. These cognitive challenges are thought to arise due to the effects of dystrophin deficiency on neuronal tissues, as dystrophin is critical not only for muscle integrity but also for brain function. Recognizing this link is essential for comprehensive care and support for individuals with BMD, highlighting the need for cognitive assessments and interventions to address potential intellectual developmental disorders in this population."
    },
    "65cfdf1c1930410b13000028":
    {
        "question": "Mutation of which gene was implicated in Disabling pansclerotic morphea?",
        "llm_evidence": "Disabling pansclerotic morphea, a severe form of localized scleroderma characterized by extensive skin and tissue hardening, has been associated with genetic mutations. Key insights indicate that mutations in the *COL6A3* gene, which encodes a component of collagen type VI, have been implicated in this condition. Collagen type VI is crucial for maintaining connective tissue integrity. Defects in this gene can lead to altered collagen production and structural anomalies, contributing to the fibrotic processes observed in pansclerotic morphea. Additionally, there have been observations of other genetic factors, such as variations in the *TGFB1* gene, which may also play a role in the pathogenesis by influencing fibrosis and immune responses. These genetic insights support the understanding of disabling pansclerotic morphea's underlying mechanisms and highlight the significance of collagen-related pathways in its development."
    },
    "662fc122187cba990d000012":
    {
        "question": "Does physical exercise reduce the risk of recurrence from colorectal cancer?",
        "llm_evidence": "Numerous studies have indicated that physical exercise can significantly reduce the risk of recurrence for colorectal cancer. Research has demonstrated that regular physical activity helps improve overall health, enhances immune function, and lowers levels of inflammation—all of which are beneficial in cancer prevention and management. A meta-analysis of observational studies showed that patients who engaged in moderate to vigorous exercise post-diagnosis had a notably lower risk of colorectal cancer recurrence compared to their sedentary counterparts. Furthermore, exercise has been linked to improved quality of life and mental health for cancer survivors, which can indirectly influence recovery and recurrence rates. Therefore, incorporating physical exercise into the post-treatment regimen for colorectal cancer patients is supported by evidence as a strategy to potentially reduce recurrence risk."
    },
    "662a4b08b9f8b89d7e00000b":
    {
        "question": "Oxysterol is produced by the oxidation of what waxy, fat-like substance made in the liver?",
        "llm_evidence": "Oxysterol is produced by the oxidation of cholesterol, a waxy, fat-like substance synthesized in the liver. Cholesterol serves as a crucial component of cell membranes and is a precursor for the synthesis of steroid hormones, bile acids, and vitamin D. The oxidation of cholesterol yields various oxysterols, which play important roles in regulating cholesterol homeostasis, inflammation, and cellular signaling pathways. Elevated levels of certain oxysterols are associated with various metabolic disorders, highlighting the significance of cholesterol oxidation in physiological and pathological processes."
    },
    "65f84c78c4010b4d78000049":
    {
        "question": "Is bowel transplantation commonly performed in patients with severe gastrointestinal disease?",
        "llm_evidence": "Bowel transplantation is a complex and specialized procedure that is not commonly performed compared to other organ transplants, primarily due to the technical challenges and the specific criteria for patient selection. It is typically indicated for patients with severe gastrointestinal diseases such as short bowel syndrome, severe Crohn's disease, or other irreversible intestinal conditions that result in intestinal failure. Early acceptance criteria required patients to demonstrate a significant loss of bowel function, with total parenteral nutrition (TPN) dependence being a key indicator. \n\nIn recent years, advancements in surgical techniques, immunosuppressive therapies, and post-operative care have improved outcomes, but the procedure remains relatively rare. According to data, only a few hundred bowel transplants are performed annually worldwide, mostly in specialized transplant centers. Furthermore, the long-term survival rates for bowel transplants, although improved, still reflect the challenges associated with organ rejection and complications, making it a less mainstream option. Therefore, while bowel transplantation is a critical treatment for select patients with life-threatening intestinal diseases, its application is limited and performed only for specific cases where other treatments have failed."
    },
    "6630154c187cba990d000021":
    {
        "question": "Which chromosome is most commonly affected by loss of heterozygosity in glioblastoma?",
        "llm_evidence": "In glioblastoma, loss of heterozygosity (LOH) most commonly affects chromosome 10. Studies have shown that approximately 50-70% of glioblastoma patients exhibit LOH on chromosome 10, which is often associated with the deletion of the 10q region. This chromosomal alteration is significant as it is linked to the inactivation of key tumor suppressor genes, including PTEN and others, contributing to the aggressive nature of glioblastoma and its poor prognosis. Additionally, LOH on chromosome 10 serves as a common genetic marker used in the characterization and diagnosis of glioblastoma, making it a focal point in cancer research and treatment strategies."
    },
    "663023f3187cba990d000030":
    {
        "question": "What is KineDMD?",
        "llm_evidence": "KineDMD (Kinematic Disease Model for Duchenne Muscular Dystrophy) is a computational tool designed to simulate and analyze the progression of Duchenne Muscular Dystrophy (DMD), a genetic disorder characterized by progressive muscle degeneration and weakness. This model leverages kinematic data—information about the motion of limbs and body segments—to assess functional changes over time in patients. \n\nKey insights include:\n1. **Simulation of Disease Progression**: KineDMD allows researchers and clinicians to visualize how DMD affects motor function, enabling better understanding and prediction of disease progression for individual patients.\n2. **Personalized Treatment**: By integrating patient-specific data, KineDMD supports the development of tailored therapeutic strategies and interventions, which can lead to improved patient outcomes.\n3. **Research and Validation**: The model serves as a platform for testing new treatments and understanding their potential effects, thereby aiding in clinical trial design and enhancing the efficacy of therapeutic approaches.\n\nOverall, KineDMD represents a significant advancement in personalized medicine for DMD, providing critical insights into the mechanics of the disease and facilitating improved care for affected individuals."
    },
    "65d12a181930410b1300002f":
    {
        "question": "Can fluoroquinolones be used for patient with myasthenia gravis?",
        "llm_evidence": "Fluoroquinolones, a class of broad-spectrum antibiotics, can pose significant risks for patients with myasthenia gravis (MG). This condition is characterized by weakness and rapid fatigue of voluntary muscles due to a communication breakdown between nerves and muscles. Several studies and clinical reports have indicated that fluoroquinolones may exacerbate muscle weakness in these patients, leading to severe respiratory issues or myasthenic crises. Specifically, the U.S. Food and Drug Administration (FDA) has issued warnings that fluoroquinolones can interfere with neuromuscular function and may worsen symptoms in individuals with MG. Therefore, despite their efficacy in treating various infections, fluoroquinolones are generally not recommended for patients with myasthenia gravis unless the potential benefits outweigh the risks, and alternative antibiotics should be considered."
    },
    "66099eb9fdcbea915f000026":
    {
        "question": "Are BRAF V600E mutation associated to worse prognosis in colorectal cancer patients?",
        "llm_evidence": "The BRAF V600E mutation is associated with a worse prognosis in colorectal cancer (CRC) patients. Studies have shown that CRC patients with the BRAF V600E mutation tend to have poorer overall survival and disease-free survival compared to those without the mutation. This mutation is often linked to a more aggressive disease phenotype, increased likelihood of metastasis, and reduced response to standard therapies, including anti-EGFR agents. Additionally, BRAF V600E mutations are frequently found in patients with mismatch repair-deficient tumors, which complicates treatment outcomes further. Overall, the presence of the BRAF V600E mutation is considered a negative prognostic factor in colorectal cancer, impacting both clinical outcomes and treatment strategies."
    },
    "662cfadc187cba990d000006":
    {
        "question": "Circular RNAs (circRNAs) are a distinct family of RNAs, how are they derived?",
        "llm_evidence": "Circular RNAs (circRNAs) are derived from pre-mRNA through a process called back-splicing. In this process, a downstream splice donor site is joined to an upstream splice acceptor site, creating a covalently closed circular molecule rather than a linear RNA transcript. This back-splicing can occur during the normal splicing of pre-mRNA and is facilitated by specific RNA binding proteins and intronic sequences that promote the circularization. CircRNAs can originate from various genomic regions, including exons, introns, and intergenic regions, contributing to their diverse forms and functions. Furthermore, they exhibit stability due to their circular structure, making them resistant to exonuclease degradation, which allows them to accumulate in cells and participate in regulatory roles such as sponging microRNAs and interacting with proteins. This distinct biogenesis pathway sets circRNAs apart from linear RNAs, highlighting their unique properties and potential functional implications in gene regulation."
    },
    "66169f9bfdcbea915f000057":
    {
        "question": "Transgender identity and mortality.",
        "llm_evidence": "Transgender individuals face significant health disparities that contribute to higher mortality rates compared to their cisgender counterparts. Key insights include:\n\n1. **Mental Health Challenges**: Transgender people are at an increased risk for mental health issues, such as depression and anxiety, often stemming from discrimination, stigma, and social isolation. These factors can lead to higher rates of suicide, which is a critical component of mortality in this population.\n\n2. **Access to Healthcare**: Many transgender individuals encounter barriers to accessing healthcare, including discrimination from healthcare providers and lack of knowledgeable care. This leads to unmet healthcare needs, which can exacerbate physical and mental health conditions.\n\n3. **Substance Abuse**: Higher rates of substance abuse disorders have been documented among transgender individuals, often as a coping mechanism for dealing with societal rejection and stress. Substance abuse can increase the risk of mortality through overdose and other related health issues.\n\n4. **Violence and Discrimination**: Transgender individuals, particularly transgender women of color, are disproportionately victimized by violence, leading to fatal outcomes. The rates of homicide in this subgroup underscore the lethal consequences of transphobia.\n\n5. **Chronic Health Issues**: Transgender individuals may neglect preventive healthcare treatments due to fear of discrimination or lack of supportive environments, resulting in higher prevalence of chronic diseases that can contribute to mortality.\n\nIn summary, the intersection of mental health issues, healthcare access challenges, violence, and chronic health conditions significantly influences the mortality risk among transgender individuals."
    },
    "663016bb187cba990d000023":
    {
        "question": "Which genetic alteration is most commonly associated with the classical subtype of glioblastoma?",
        "llm_evidence": "The classical subtype of glioblastoma is most commonly associated with alterations in the epidermal growth factor receptor (EGFR) gene. This subtype frequently exhibits EGFR amplification and often presents with mutations leading to the expression of a constitutively active variant known as EGFRvIII. Additional key genetic alterations frequently found in this subtype include the loss of heterozygosity on chromosome 10, especially involving the PTEN tumor suppressor gene. These genetic changes contribute to the aggressive nature and characteristic behavior of classical glioblastomas, making them distinct from other subtypes."
    },
    "66302487187cba990d000031":
    {
        "question": "What is PUL-2 in Duchenne Muscular Dystrophy?",
        "llm_evidence": "PUL-2 refers to the second version of the Performance of Upper Limb (PUL) scale, which is a tool specifically designed to assess upper limb function in patients with Duchenne Muscular Dystrophy (DMD). The PUL is particularly relevant for DMD, a genetic disorder characterized by progressive muscle degeneration and weakness. PUL-2, an updated version, includes refined criteria for measuring upper limb capabilities, focuses on the functional abilities necessary for daily living, and enhances the sensitivity of detecting changes over time in a patient's upper extremity function. The scale includes various tasks ranging from simple movements to more complex activities, allowing clinicians to gauge the impact of therapeutic interventions and track disease progression in individuals with DMD. The use of PUL-2 has become important in clinical trials and practice, as it provides quantitative data that can help in managing care and assessing treatment efficacy."
    },
    "65cfac201930410b13000013":
    {
        "question": "What is the mechanism of action of Mezigdomide?",
        "llm_evidence": "Mezigdomide is an immunomodulatory drug (IMiD) designed to target the cereblon (CRBN) E3 ubiquitin ligase complex. Its mechanism of action involves binding to cereblon, which leads to the targeted degradation of specific transcription factors, such as Ikaros (IKZF1) and Aiolos (IKZF3). This degradation alters the expression of genes involved in immune regulation and enhances antitumor activity by promoting the apoptosis of malignant cells, particularly in hematological malignancies like multiple myeloma. Additionally, Mezigdomide has been shown to stimulate T-cell and natural killer (NK) cell activities, further contributing to its efficacy against cancer. Overall, the dual action of targeting tumor cells and enhancing immune responses underpins its therapeutic potential."
    },
    "66099907fdcbea915f000015":
    {
        "question": "What is the average median survival for advanced colorectal cancer patients?",
        "llm_evidence": "The average median survival for advanced colorectal cancer patients varies based on numerous factors, including the treatment regimen and individual patient characteristics. Generally, for patients with metastatic colorectal cancer, the median survival is estimated to be between 24 to 30 months with modern therapies such as targeted treatments and immunotherapy. These survival rates have improved with advancements in treatment, including the use of combination chemotherapy (e.g., FOLFOX, FOLFIRI) and biological agents (e.g., cetuximab, bevacizumab). Additionally, factors such as the patient's overall health, response to treatment, and the presence of specific genetic mutations can significantly influence survival outcomes. Overall, while the prognosis for advanced colorectal cancer remains challenging, ongoing research and treatment innovations have shown promise in extending survival times."
    },
    "662cfa24187cba990d000005":
    {
        "question": "What is the function of the mTORC1 kinase?",
        "llm_evidence": "The mTORC1 (mammalian Target of Rapamycin Complex 1) kinase is a critical regulator of cellular growth and metabolism. It integrates signals from nutrients, growth factors, and cellular energy status to coordinate various biological processes. Key functions of mTORC1 include:\n\n1. **Protein Synthesis**: mTORC1 promotes protein synthesis by activating key translation factors, such as S6K1 and 4E-BP1, contributing to cell growth and proliferation.\n\n2. **Cell Growth and Proliferation**: It plays a vital role in cell size and growth by responding to growth factors like insulin and nutrients (e.g., amino acids), thereby driving cellular processes that support proliferation.\n\n3. **Metabolism Regulation**: mTORC1 influences metabolic pathways by promoting anabolic processes (such as lipid and nucleotide synthesis) while inhibiting catabolic processes like autophagy, thus ensuring that cells conserve resources in favorable conditions.\n\n4. **Response to Stress**: mTORC1 activity is modulated in response to cellular stressors; under low nutrient or energy conditions, its activity is inhibited, allowing cells to conserve energy and enter a survival mode.\n\nIn summary, mTORC1 is essential for regulating growth, metabolism, and cellular responses to environmental stimuli, making it a key player in maintaining cellular homeostasis and function."
    },
    "6616a122fdcbea915f000058":
    {
        "question": "Has statin use been associated with a higher risk of dementia?",
        "llm_evidence": "Research on the association between statin use and dementia risk has produced mixed results. Some studies suggest that long-term statin use may be linked to a reduced risk of developing dementia, particularly Alzheimer's disease, by improving cardiovascular health and promoting better blood flow to the brain. However, other studies have indicated a potential increased risk of cognitive decline or dementia in certain populations, particularly among older adults. \n\nKey insights include:\n\n1. **Cardiovascular Health**: Statins lower cholesterol levels, which may help prevent vascular dementia by enhancing blood circulation in the brain. \n\n2. **Confounding Factors**: Many studies do not adequately control for confounding factors such as age, comorbidities, and the baseline cognitive function of participants, leading to ambiguous conclusions.\n\n3. **Meta-Analyses**: Some meta-analyses have reported no significant association between statin use and increased dementia risk, indicating a more protective effect, especially when initiated early in life.\n\n4. **Cognitive Side Effects**: While statins can cause cognitive-related side effects in some individuals—typically reversible upon discontinuation—these instances are not widespread and often do not outweigh their cardiovascular benefits.\n\nOverall, the evidence remains inconclusive, with the potential for both protective and harmful effects depending on individual health profiles and the type of dementia considered. Further research is needed to clarify these associations."
    },
    "6630254b187cba990d000032":
    {
        "question": "Is DNA methylation always associated with gene silencing?",
        "llm_evidence": "DNA methylation is a nuanced epigenetic mechanism that is often, but not always, associated with gene silencing. Typically, the addition of methyl groups to cytosine residues in DNA, particularly in promoter regions, can inhibit gene transcription by preventing the binding of transcription factors or by recruiting repressive proteins. However, the relationship between DNA methylation and gene expression is complex and context-dependent.\n\n1. **Context-specific roles**: While hypermethylation in promoter regions is frequently linked to silenced genes, hypomethylation in gene bodies can be associated with active transcription, indicating a dual role in gene regulation.\n\n2. **Tissue-specific patterns**: Methylation patterns can vary widely across different tissues and developmental stages, with some genes being expressed in specific contexts despite local methylation.\n\n3. **Transcriptional activation**: In certain cases, DNA methylation can facilitate transcriptional activation through mechanisms not fully understood, suggesting that it can have roles beyond just repression.\n\n4. **Environmental influence**: Factors such as environmental signals and developmental cues can modulate the effect of methylation on gene expression, making it essential to consider these influences when assessing the impact of methylation.\n\nIn summary, while DNA methylation is commonly associated with gene silencing, it is not an absolute rule, with several exceptions and varying contexts that demonstrate a more complex relationship between methylation and gene expression."
    },
    "66302174187cba990d00002e":
    {
        "question": "Are there any digital biomarkers for Duchenne Muscular Dystrophy?",
        "llm_evidence": "Yes, there are emerging digital biomarkers for Duchenne Muscular Dystrophy (DMD), which are essential for monitoring disease progression and treatment efficacy. Recent studies have employed wearable technology and mobile applications that track various physiological parameters such as muscle strength, mobility, and fatigue levels. For instance, sensors can detect changes in gait patterns, while accelerometers and smart devices can monitor daily physical activity levels and quantify mobility impairments. Additionally, digital tools like machine learning algorithms are being utilized to analyze data collected from these devices, potentially identifying early signs of muscle degeneration and aiding in clinical decision-making. These digital biomarkers offer the promise of more personalized and timely interventions for patients with DMD, enhancing care and improving outcomes."
    },
    "65cfd2681930410b1300001e":
    {
        "question": "How should Insulin icodec be administered?",
        "llm_evidence": "Insulin icodec is a long-acting insulin analog designed for once-weekly administration in patients with type 2 diabetes. Its key pharmacokinetic profile allows for sustained glucose control with a single subcutaneous injection. Administration should take place at the same day and time each week to maintain stable insulin levels. It can be injected into the abdomen, thigh, or upper arm, ensuring that the injection site is rotated to prevent lipodystrophy. Patients should be educated on self-administration techniques, including proper handling of the insulin pen and recognition of potential side effects, particularly hypoglycemia. Regular monitoring of blood glucose levels is essential to adjust the dosage as needed."
    },
    "66099ba9fdcbea915f000022":
    {
        "question": "Is FOLFIRI plus Aflibercept a cost-effective treatment in patients with advanced colorectal caner?",
        "llm_evidence": "FOLFIRI (a combination of fluorouracil, leucovorin, and irinotecan) plus Aflibercept (a vascular endothelial growth factor inhibitor) has been assessed for its cost-effectiveness in patients with advanced colorectal cancer (CRC). Key insights include:\n\n1. **Clinical Efficacy**: Studies indicate that FOLFIRI plus Aflibercept improves progression-free survival and overall survival compared to FOLFIRI alone. This therapeutic benefit can justify higher costs associated with the addition of Aflibercept.\n\n2. **Economic Evaluations**: Health economic analyses often employ models to assess the cost-effectiveness of treatments for CRC. These studies typically show that while the upfront costs for FOLFIRI plus Aflibercept are higher, the gain in quality-adjusted life years (QALYs) can make the therapy cost-effective depending on the willingness-to-pay threshold set by healthcare systems.\n\n3. **Budget Impact**: The treatment's cost-effectiveness varies by healthcare system and reimbursement policies. In some analyses, the high costs associated with Aflibercept may be a concern for budget-constrained healthcare settings. However, it may still be seen as cost-effective when considering the potential for reduced downstream costs (e.g., decreased hospitalization due to better disease control).\n\n4. **Sensitivity Analyses**: Multiple studies incorporate sensitivity analyses to evaluate how variations in drug prices, treatment adherence, and patient response impact cost-effectiveness, suggesting that under various scenarios, FOLFIRI plus Aflibercept remains a viable option in certain patient populations.\n\nIn conclusion, while the treatment is associated with higher costs, its clinical efficacy and the potential for enhancing patient outcomes can lead to a conclusion of cost-effectiveness in advanced colorectal cancer settings, particularly tailored to specific patient characteristics and healthcare contexts."
    },
    "662cf96f187cba990d000004":
    {
        "question": "Please list some treatment options for bone marrow edema syndrome,",
        "llm_evidence": "Bone marrow edema syndrome (BMES) is characterized by pain and swelling due to abnormal fluid accumulation in the bone marrow. Treatment options can vary based on the underlying cause and severity of symptoms, but some common approaches include:\n\n1. **Medication**: Non-steroidal anti-inflammatory drugs (NSAIDs) can help reduce pain and inflammation. In some cases, corticosteroids may be prescribed to alleviate more severe symptoms.\n\n2. **Physical Therapy**: Engaging in guided physical therapy can help improve mobility and strengthen the surrounding muscles, which may reduce stress on the affected bone.\n\n3. **Rest and Activity Modification**: Limiting weight-bearing activities and providing adequate rest to the affected limb can facilitate healing.\n\n4. **Bone Support Devices**: Using braces or orthotic devices can help offload pressure from the affected area, providing additional support during the healing process.\n\n5. **Injections**: In certain instances, intra-articular injections of corticosteroids or hyaluronic acid may be used to deliver localized relief.\n\n6. **Surgery**: In cases where conservative treatments fail or if there is significant underlying pathology (like osteonecrosis), surgical interventions such as core decompression may be considered.\n\nThese treatment strategies aim to alleviate symptoms, promote healing, and improve overall function in individuals affected by BMES."
    },
    "66150639fdcbea915f000047":
    {
        "question": "What is the immediate treatment after a sexual assault?",
        "llm_evidence": "Immediate treatment after a sexual assault focuses on both medical and psychological support. Key steps include:\n\n1. **Safety and Support**: The first priority is ensuring the survivor's physical safety. They should be in a secure environment, away from the assailant, and may need emotional support from a trusted friend, family member, or a crisis counselor.\n\n2. **Medical Attention**: Survivors are advised to seek medical care as soon as possible, ideally within 72 hours. Medical professionals can provide necessary care for injuries, sexually transmitted infections (STIs), and pregnancy prevention, and perform forensic examinations if the survivor chooses to collect evidence.\n\n3. **Forensic Examination**: A Sexual Assault Nurse Examiner (SANE) can conduct a thorough examination to collect evidence without compromising the survivor’s autonomy. This can include swabs, swabs for DNA evidence, and the collection of clothing for forensic analysis.\n\n4. **Crisis Counseling**: Access to mental health professionals experienced in trauma can greatly help survivors process their experience, providing support to address immediate emotional distress and longer-term psychological healing.\n\n5. **Reporting Options**: Survivors should be informed about their options regarding reporting the assault to law enforcement and the implications of each choice, empowering them to make decisions that are right for them.\n\nOverall, immediate treatment after a sexual assault is centered on safety, medical care, emotional support, and informed decision-making."
    },
    "6630562c187cba990d000036":
    {
        "question": "What is the potential role of the tumor microenvironment and factors like stem cells in contributing to the recurrence of glioblastoma?",
        "llm_evidence": "The tumor microenvironment (TME) plays a crucial role in glioblastoma recurrence by influencing tumor behavior and treatment resistance. Key components of the TME, including immune cells, blood vessels, extracellular matrix, and signaling molecules, create a supportive niche for tumor growth and survival. \n\nCancer stem cells (CSCs), a subset of cells within the glioblastoma, are particularly implicated in recurrence due to their abilities to self-renew and differentiate into more tumor cells. CSCs can evade conventional therapies, leading to tumor regrowth after initial treatment. The TME contributes to CSC maintenance and proliferation through various mechanisms, such as promoting immunosuppressive signals and providing survival factors that enhance CSC properties.\n\nMoreover, the intercellular communication within the TME, including exosomes and cytokine signaling, further supports glioblastoma's resilience against therapeutic interventions. This complex interaction between the TME and CSCs creates significant hurdles in achieving durable responses to treatment, ultimately leading to glioblastoma recurrence. Understanding these interactions is vital for developing more effective therapies aimed at targeting the TME and CSCs to prevent glioblastoma relapse."
    },
    "663020d7187cba990d00002b":
    {
        "question": "Is there an association between specific genotypes and the risk of ADHD for Duchenne Muscular Dystrophy?",
        "llm_evidence": "Research indicates that there may be a notable association between specific genotypes and the risk of Attention Deficit Hyperactivity Disorder (ADHD) in individuals with Duchenne Muscular Dystrophy (DMD). Studies have shown that certain genetic polymorphisms, particularly in genes related to neurodevelopment and neurotransmitter systems, could influence the likelihood of developing ADHD in this population. For instance, variants in the dopamine transporter gene (DAT1) and the serotonin transporter gene (5-HTTLPR) have been examined for their role in ADHD risk. Additionally, the phenotypic overlap between DMD and ADHD symptoms, such as behavioral challenges and cognitive deficits, suggests a potential shared genetic vulnerability. Given the complex interplay of genetics and the neurological impact of DMD, further research is essential to establish definitive associations and underlying mechanisms. Overall, these insights support the hypothesis of a genotype-ADHD risk link within the context of DMD."
    },
    "65cfd8551930410b13000023":
    {
        "question": "Is vemurafenib–cobimetinib promising for craniopharyngioma?",
        "llm_evidence": "Vemurafenib and cobimetinib are targeted therapies that have shown effectiveness in treating melanoma by inhibiting the BRAF and MEK pathways, respectively. Craniopharyngiomas are tumors that can exhibit alterations in the BRAF gene, particularly in the subtype known as adamantinomatous craniopharyngioma. Evidence suggests that targeting these pathways may be beneficial in managing this tumor type, especially for patients with BRAF V600E mutations.\n\nClinical studies have reported encouraging results with the use of vemurafenib in patients who have BRAF-mutated tumors, leading to significant tumor regression in some cases. Cobimetinib, as a MEK inhibitor, may enhance the efficacy of vemurafenib by preventing feedback mechanisms that can lead to resistance.\n\nOverall, the combination of vemurafenib and cobimetinib presents a promising therapeutic strategy for treating craniopharyngioma with BRAF mutations, with ongoing research needed to fully establish their safety and efficacy in this context."
    },
    "66214db9b9f8b89d7e000004":
    {
        "question": "What is the molecular mechanism by which Bacteroides Fragilis is associated to colorectal cancer development?",
        "llm_evidence": "Bacteroides fragilis, a prominent member of the gut microbiota, has been linked to colorectal cancer (CRC) through several molecular mechanisms. One key finding is the production of a specific enterotoxin known as Bacteroides fragilis toxin (BFT), which can induce pro-inflammatory responses and alter cellular signaling pathways. BFT promotes the overexpression of cytokines such as IL-17 and TNF-α, leading to chronic inflammation, a well-known risk factor for CRC.\n\nFurthermore, B. fragilis can disrupt the mucosal barrier and promote the translocation of bacteria and their products into the gut tissue, exacerbating inflammation. It can also influence the host immune response by modulating T cell populations, contributing to a shift towards a more inflammatory environment that favors tumorigenesis.\n\nAdditionally, B. fragilis is involved in the metabolism of dietary components, affecting the production of short-chain fatty acids (SCFAs) which play a role in maintaining gut homeostasis. An imbalance in SCFA production can disrupt epithelial integrity and promote malignant transformation.\n\nIn summary, Bacteroides fragilis is associated with colorectal cancer development through the production of inflammatory toxins, disruption of gut mucosal barriers, and alterations in immune responses and gut metabolism, culminating in a pro-carcinogenic environment."
    },
    "662cfbf5187cba990d000007":
    {
        "question": "Where in the body would the globus pallidus be found?",
        "llm_evidence": "The globus pallidus is located within the basal ganglia of the brain. It is situated deep within the cerebral hemispheres, specifically nestled beneath the cortex and adjacent to the putamen. The globus pallidus is divided into two segments: the internal segment (GPi) and the external segment (GPe). It plays a crucial role in the regulation of voluntary movement and is involved in the modulation of motor activity and the coordination of movements."
    },
    "66151045fdcbea915f000048":
    {
        "question": "What is the approximate prevalence of autoimmune diseases?",
        "llm_evidence": "Autoimmune diseases affect a significant portion of the population, with estimates suggesting that around 3-5% of individuals in Western countries are affected by these conditions. The prevalence varies by specific autoimmune diseases; for example, rheumatoid arthritis affects about 0.5-1% of the population, while lupus has a prevalence of about 0.001-0.1%. Women are disproportionately affected, with some studies indicating that around 75% of autoimmune disease patients are female. Environmental factors, genetic predispositions, and infections are considered contributing factors to the development of these diseases. Overall, the increasing awareness and diagnosis of autoimmune diseases have led to a rise in reported prevalence rates in recent years."
    },
    "662ee24a187cba990d00000d":
    {
        "question": "What is the role of Isocitrate dehydrogenase (IDH) mutations in glioma?",
        "llm_evidence": "Isocitrate dehydrogenase (IDH) mutations play a significant role in the development and progression of gliomas, particularly in lower-grade gliomas and secondary glioblastomas. These mutations result in a gain-of-function that alters cellular metabolism, specifically shifting the metabolic pathway from oxidative phosphorylation to aerobic glycolysis. This metabolic reprogramming leads to the accumulation of 2-hydroxyglutarate (2-HG), an oncometabolite that disrupts normal cellular functions, including histone and DNA methylation processes, contributing to tumorigenesis.\n\nClinically, IDH mutations are associated with a more favorable prognosis and distinct morphological features when compared to IDH wild-type gliomas. Moreover, IDH mutations serve as important biomarkers for diagnosis and have implications for therapeutic strategies, as the presence of the mutation can influence the response to certain treatments. Overall, IDH mutations are pivotal in glioma biology and represent a target for potential therapeutic interventions."
    },
    "66301fcb187cba990d000029":
    {
        "question": "Is there an association between specific genotypes and the risk of neurodevelopmental disorders for Becker Muscular Dystrophy?",
        "llm_evidence": "Becker Muscular Dystrophy (BMD) is caused by mutations in the dystrophin gene, and while primarily characterized by muscle degeneration, emerging research has indicated a potential association between specific genotypes and neurodevelopmental disorders (NDDs). Studies show that certain dystrophin mutations, particularly those that lead to atypical dystrophin isoforms, may correlate with cognitive impairment and developmental delays. This association seems to be more pronounced in cases where mutations disrupt the brain-specific isoform of dystrophin, which plays a crucial role in neuroprotection and neuronal function. Additionally, the presence of specific polymorphisms in related genes can influence the severity of cognitive and behavioral outcomes in affected individuals. Therefore, while BMD is primarily a muscular disorder, there is evidence to suggest that certain genotypes linked to the dystrophin gene may also elevate the risk of neurodevelopmental disorders."
    },
    "65d375b31930410b1300004b":
    {
        "question": "What medication are included in the Juvisync pill?",
        "llm_evidence": "Juvisync is a combination medication that includes two active ingredients: sitagliptin and simvastatin. Sitagliptin is an oral hypoglycemic agent used to improve blood sugar control in adults with type 2 diabetes by increasing insulin secretion and decreasing glucose production. Simvastatin is a statin used to lower cholesterol levels and reduce the risk of cardiovascular diseases. The combination of these two medications in Juvisync is designed to help manage both blood sugar levels and cholesterol, addressing two significant health concerns that often co-occur in patients with type 2 diabetes."
    },
    "66214cc6b9f8b89d7e000003":
    {
        "question": "Is fish intake a protective factor against colorectal cancer?",
        "llm_evidence": "Numerous studies suggest that fish intake may be a protective factor against colorectal cancer. Fish, particularly fatty fish rich in omega-3 fatty acids (such as salmon, mackerel, and sardines), are associated with anti-inflammatory properties that could play a role in cancer prevention. Omega-3 fatty acids have been shown to inhibit the growth of cancer cells and reduce the risk of tumor development. Additionally, fish is a key source of vitamin D and other nutrients that may contribute to overall digestive health.\n\nEpidemiological studies have indicated that higher fish consumption correlates with lower rates of colorectal cancer. A meta-analysis found that individuals who regularly consume fish have a significantly reduced risk compared to those with low or no intake. The protective effect seems to be more pronounced in populations that have a dietary pattern rich in seafood. Furthermore, the substitution of fish for red or processed meats—known risk factors for colorectal cancer—could also lower cancer risk.\n\nIn conclusion, while more research is needed to establish causation definitively, the evidence indicates that regular fish intake may play a beneficial role in reducing the risk of colorectal cancer."
    },
    "6616b259fdcbea915f00005a":
    {
        "question": "What is the exposome?",
        "llm_evidence": "The exposome refers to the cumulative measure of environmental exposures an individual experiences throughout their lifetime, encompassing all factors outside of genetics, including diet, lifestyle, pollutants, and social interactions. It aims to capture the totality of environmental influences on health, which is believed to play a significant role in the development of diseases alongside genetic factors. The exposome can be divided into two components: the external exposome (environmental exposures such as air and water quality, chemical exposures, and socioeconomic factors) and the internal exposome (biological responses and metabolic reactions to external exposures). Understanding the exposome is crucial for identifying associations between environmental factors and health outcomes, informing public health policies, and developing personalized medicine approaches."
    },
    "66156200fdcbea915f00004d":
    {
        "question": "What is the gold standard for a diagnosis of narcolepsy?",
        "llm_evidence": "The gold standard for diagnosing narcolepsy is a combination of clinical evaluation and objective testing, primarily through a Multiple Sleep Latency Test (MSLT) and Polysomnography (PSG). The MSLT measures how quickly a person falls asleep in a quiet environment during the day, assessing daytime sleepiness and the presence of rapid eye movement (REM) sleep episodes. A key characteristic of narcolepsy is the occurrence of REM sleep within 15 minutes of sleep onset during the MSLT, alongside excessive daytime sleepiness. Additionally, PSG conducted overnight can help identify disrupted sleep patterns and confirm the presence of REM sleep phenomena. The diagnosis is often corroborated by patient history and the presence of symptoms like cataplexy, hypnagogic hallucinations, and sleep paralysis, further solidifying the diagnosis based on established criteria from the International Classification of Sleep Disorders."
    },
    "6630390b187cba990d000035":
    {
        "question": "Which receptor tyrosine kinase is commonly mutated or amplified in pediatric glioma cases?",
        "llm_evidence": "In pediatric glioma cases, the receptor tyrosine kinase commonly mutated or amplified is the **platelet-derived growth factor receptor alpha (PDGFRA)**. Studies have shown that alterations in PDGFRA are frequently observed in various subtypes of pediatric gliomas, including high-grade gliomas and diffuse intrinsic pontine gliomas (DIPG). These mutations or amplifications often lead to increased signaling through the PI3K-AKT and RAS-MAPK pathways, promoting tumor growth and survival. Additionally, alterations in the PDGFRA gene have been associated with poorer prognosis, highlighting its significance as a therapeutic target in pediatric brain tumors."
    },
    "66300c23187cba990d00001a":
    {
        "question": "Can procalcitonin be used as a predictor for mortality in paediatric sepsis?",
        "llm_evidence": "Procalcitonin (PCT) has been studied as a biomarker in various clinical settings, including paediatric sepsis. Research indicates that elevated levels of procalcitonin are associated with severe bacterial infections and can correlate with disease severity. In paediatric populations, several studies have shown that higher PCT levels upon admission are linked to increased mortality rates. \n\nFor instance, a systematic review of studies on paediatric sepsis concluded that PCT is useful not only in diagnosing sepsis but also in assessing the prognosis, including mortality risk. Elevated PCT levels can help clinicians identify children at higher risk of poor outcomes, allowing for more timely and aggressive management. \n\nAdditionally, PCT levels can also aid in monitoring treatment response; a decrease in PCT levels may indicate a positive response to therapy, while persistently high levels might suggest ongoing infection or clinical deterioration. \n\nOverall, the evidence supports the use of procalcitonin as a reliable predictor of mortality in paediatric sepsis, underscoring its value in clinical decision-making and risk stratification."
    },
    "66214c5db9f8b89d7e000002":
    {
        "question": "What is the race with the highest incidence of colorectal cancer?",
        "llm_evidence": "Colorectal cancer incidence rates vary significantly among different racial and ethnic groups. Data indicates that African Americans have the highest incidence of colorectal cancer compared to other racial groups in the United States. Studies show that African American men and women are diagnosed at younger ages and have higher mortality rates from the disease. Contributing factors include disparities in access to healthcare, variations in genetic susceptibility, lifestyle factors, and socioeconomic challenges. Public health initiatives are focusing on increasing screening and awareness among African Americans to address this disparity and improve outcomes."
    },
    "662cfd21187cba990d000009":
    {
        "question": "LRP6 is a member of what  superfamily of cell-surface receptors?",
        "llm_evidence": "LRP6 is a member of the low-density lipoprotein receptor (LDLR) superfamily of cell-surface receptors. This superfamily is characterized by their role in mediating various biological processes, including lipid metabolism, endocytosis, and cell signaling. LRP6 specifically functions as a co-receptor in the Wnt signaling pathway, which is critical for development and stem cell regulation. It interacts with Wnt ligands and enhances signal transduction, thereby influencing cellular pathways essential for tissue homeostasis and growth."
    },
    "661686e4fdcbea915f000052":
    {
        "question": "List of major risks of intrauterine device.",
        "llm_evidence": "Intrauterine devices (IUDs) are generally safe and effective contraceptive options, but they do come with several significant risks. Key insights include:\n\n1. **Perforation of the Uterus**: Although rare, there is a small risk (approximately 1 in 1,000 insertions) that the IUD can perforate the uterine wall during placement, which may require surgical intervention.\n\n2. **Expulsion**: IUDs can sometimes be expelled from the uterus, which is more common in women who have never been pregnant or those who are younger. Expulsion rates can range from 2% to 10%.\n\n3. **Ectopic Pregnancy**: While IUDs significantly reduce the overall risk of pregnancy, if a pregnancy does occur, there is an increased chance it may be ectopic—occurring outside the uterus, which can be a medical emergency.\n\n4. **Pelvic Inflammatory Disease (PID)**: There is a risk of developing PID, especially within the first few weeks after insertion. PID can lead to chronic pain and fertility issues.\n\n5. **Menstrual Changes**: Users might experience heavier menstrual bleeding, longer periods, or severe cramping, particularly with copper IUDs. Hormonal IUDs may reduce menstrual flow over time.\n\n6. **Sepsis**: Though extremely rare, there is a potential risk of sepsis (a severe infection) linked to IUD placement, particularly in the context of existing sexually transmitted infections.\n\n7. **Malpositioning**: In some cases, the IUD may not be positioned correctly within the uterus, leading to ineffective contraception and potential complications.\n\nThese risks highlight the importance of appropriate patient selection, careful insertion by trained professionals, and ongoing monitoring in women who choose to use IUDs for contraception."
    },
    "66301e04187cba990d000027":
    {
        "question": "What are episignatures?",
        "llm_evidence": "Episignatures are specific patterns in the epigenetic modifications of DNA that can signify the presence of certain diseases or conditions. These signatures arise from changes such as DNA methylation or histone modification, which do not alter the genetic code but influence gene expression. In medical research, episignatures can serve as biomarkers for diseases, helping to diagnose or predict the disease severity and response to treatment. Notably, different diseases, including certain cancers and neurodegenerative disorders, exhibit distinct episignatures that can be detected and analyzed through various epigenomics techniques, making them valuable tools in precision medicine. Overall, episignatures provide insight into the epigenetic landscape associated with specific health conditions."
    },
    "66215690b9f8b89d7e00000a":
    {
        "question": "Is chemotherapy an effective treatment for patients with advance colorectal cancer and poor performance status (ECOG/PS >1)",
        "llm_evidence": "Chemotherapy can be an effective treatment for patients with advanced colorectal cancer and poor performance status (ECOG/PS >1), though its efficacy is often limited by the patient's overall health and tolerance to treatment. Studies indicate that while the prognosis is generally poorer in this group, certain regimens, particularly those including oxaliplatin or irinotecan, can offer benefits in terms of disease control and quality of life. \n\nFurthermore, research shows that patients with ECOG PS 2 or higher can still experience palliative benefits from chemotherapy, such as symptom relief and improved functional status, even if overall survival outcomes may not be significantly favorable. The choice of regimen should consider the individual's performance status, comorbidities, and the potential for treatment-related adverse effects. Therefore, while treatment may be challenging for this subgroup, it can still be justified when aiming for symptom management and possible disease stabilization."
    },
    "663027bb187cba990d000033":
    {
        "question": "How does Pamrevlumab work?",
        "llm_evidence": "Pamrevlumab is a monoclonal antibody that targets connective tissue growth factor (CTGF), a protein involved in fibrosis and tissue remodeling. By inhibiting CTGF, Pamrevlumab aims to reduce abnormal scarring and fibrosis in various conditions, particularly in diseases like idiopathic pulmonary fibrosis (IPF) and muscular dystrophies. The drug works by preventing the binding of CTGF to its receptors, thereby disrupting the signaling pathways that promote fibroblast proliferation and collagen deposition. This mechanism helps to mitigate tissue stiffness and preserve organ function, contributing to improved patient outcomes. Additionally, clinical studies have shown its potential to slow disease progression by addressing the underlying fibrotic processes."
    },
    "662fbec6187cba990d00000f":
    {
        "question": "What are the clinical indication for Transarterial Chemoembolization (TACE) in liver metastasis for colorectal cancer?",
        "llm_evidence": "Transarterial Chemoembolization (TACE) is a localized treatment option for liver metastasis from colorectal cancer, primarily indicated for patients with unresectable tumors who have not responded to systemic therapy or are not candidates for surgical resection. Key insights supporting its clinical application include:\n\n1. **Unresectability**: TACE is often considered for patients with large liver metastases or those involving multiple segments of the liver where surgical options are limited due to the extent of disease.\n\n2. **Palliation**: It is utilized for symptom management and to improve quality of life, particularly in patients experiencing pain or discomfort due to liver tumors.\n\n3. **Tumor Control**: Evidence suggests that TACE can lead to tumor shrinkage, potentially delaying disease progression and allowing for better management of the overall cancer.\n\n4. **Combination Therapy**: TACE may be used in conjunction with systemic therapies, enhancing overall treatment efficacy in controlling metastatic disease.\n\n5. **Patient Selection**: Ideal candidates typically include those with preserved liver function (Child-Pugh Class A or early B) and good performance status, enabling them to tolerate the procedure.\n\nOverall, TACE serves as a critical intervention in the management of liver metastases from colorectal cancer, especially when curative surgical options are not viable."
    },
    "663014c8187cba990d000020":
    {
        "question": "What is Alzheimer's disease?",
        "llm_evidence": "Alzheimer's disease is a progressive neurodegenerative disorder characterized by the gradual decline in cognitive function, memory, and behavior. It primarily affects the elderly and is the most common cause of dementia. Key insights include:\n\n1. **Pathophysiology**: Alzheimer's is marked by the accumulation of amyloid plaques and tau tangles in the brain, which disrupt communication between neurons and lead to cell death.\n\n2. **Symptoms**: Early symptoms often include memory loss, difficulty completing familiar tasks, and challenges with language. As the disease progresses, individuals may experience disorientation, mood swings, and changes in personality.\n\n3. **Risk Factors**: Age is the most significant risk factor, with a higher prevalence in individuals over 65. Genetic factors, such as the presence of the APOE ε4 allele, as well as lifestyle factors (e.g., diet, exercise, and cardiovascular health) also contribute to risk.\n\n4. **Diagnosis and Staging**: Alzheimer's is diagnosed through clinical assessments, cognitive tests, and neuroimaging. The disease usually progresses through stages from mild cognitive impairment to severe dementia.\n\n5. **Treatment and Management**: There is currently no cure for Alzheimer’s, but treatments are available to temporarily relieve symptoms and enhance quality of life. Research into disease-modifying therapies is ongoing.\n\nUnderstanding Alzheimer's disease involves recognizing it as a complex interplay of biological, genetic, and environmental factors that culminate in debilitating cognitive decline."
    },
    "662fbfc4187cba990d000010":
    {
        "question": "Is short-course radiation therapy a cost-effective therapy in the neoadjuvant treatment of locally advanced rectal cancer?",
        "llm_evidence": "Short-course radiation therapy (SCRT) has emerged as a cost-effective strategy in the neoadjuvant treatment of locally advanced rectal cancer. Key insights supporting this conclusion include:\n\n1. **Reduced Treatment Duration**: SCRT typically involves a shorter treatment regimen (5 days) compared to long-course radiation therapy (LCRT), which can last up to 5-6 weeks. This leads to lower direct healthcare costs associated with fewer hospital visits and reduced resource utilization.\n\n2. **Similar Efficacy**: Clinical trials have shown that SCRT can achieve comparable oncological outcomes to LCRT in terms of tumor response and rates of pathological complete response (pCR), thereby validating its use as an effective neoadjuvant treatment option.\n\n3. **Quality of Life**: Patients receiving SCRT report a better quality of life during treatment, as the shorter duration minimizes treatment-related fatigue and other side effects, ultimately contributing to fewer interruptions in daily life and potentially reducing indirect costs.\n\n4. **Overall Survival and Complication Rates**: Studies indicate that SCRT does not compromise survival rates compared to LCRT and may even reduce the incidence of treatment-related complications, further enhancing its value as a cost-effective approach.\n\n5. **Cost-Effectiveness Analyses**: Economic evaluations commonly demonstrate that SCRT results in lower overall healthcare costs when taking into account both direct costs related to treatment and the indirect cost savings from improved patient quality of life and reduced complications.\n\nIn summary, short-course radiation therapy presents a compelling case for its cost-effectiveness in the neoadjuvant treatment of locally advanced rectal cancer, highlighted by its reduced treatment duration, equivalent efficacy to long-course therapies, improved patient quality of life, and favorable economic evaluations."
    },
    "66301f5a187cba990d000028":
    {
        "question": "Are there any episignatures for Duchenne Muscular Dystrophy?",
        "llm_evidence": "Episignatures refer to specific patterns of epigenetic modifications that can serve as biomarkers for certain diseases. In the case of Duchenne Muscular Dystrophy (DMD), research has identified several potential episignatures that correlate with the disease's pathophysiology.\n\nKey insights include:\n\n1. **DNA Methylation Patterns**: Studies have demonstrated that individuals with DMD exhibit distinctive DNA methylation profiles, particularly in genes related to muscle function and inflammation. These aberrant methylation changes can serve as a potential diagnostic tool.\n\n2. **Histone Modification**: Altered histone modifications have been observed in muscle tissues of DMD patients, indicating disrupted gene expression regulation. This can be indicative of the disease's impact on muscle cells and provide insights into therapeutic targets.\n\n3. **Whole Genome Bisulfite Sequencing**: This technique has been used to map methylation changes across the genome in DMD patients, revealing specific regions that are hypermethylated or hypomethylated, which may contribute to the clinical manifestation of the disease.\n\n4. **Potential for Early Diagnosis**: The identification of these episignatures can facilitate early diagnosis and monitoring of disease progression, allowing for timely interventions and personalized treatment strategies.\n\nOverall, the exploration of episignatures in DMD shows promise for developing non-invasive biomarkers that could enhance understanding of the disease mechanisms and improve patient outcomes."
    },
    "6621506cb9f8b89d7e000007":
    {
        "question": "What are the minimum molecular determinations necessary for the initial treatment of advanced colorectal cancer in clinical practice?",
        "llm_evidence": "To effectively initiate treatment for advanced colorectal cancer (CRC), several critical molecular determinations are necessary. These include:\n\n1. **RAS Mutation Testing**: Assessing KRAS and NRAS mutations is crucial, as the presence of these mutations influences the response to anti-EGFR therapies (e.g., cetuximab and panitumumab). Patients with wild-type RAS are eligible for these targeted therapies, while those with mutations are not.\n\n2. **Microsatellite Instability (MSI) Testing**: Identifying patients with MSI-high status or mismatch repair deficiency (dMMR) is important for selecting immunotherapy options, such as pembrolizumab or nivolumab, which are more effective in these patients.\n\n3. **BRAF Mutation Analysis**: Testing for BRAF mutations (particularly BRAF V600E) is critical, as these mutations are associated with a poorer prognosis and may dictate specific treatment approaches, including combination therapies.\n\n4. **HER2 Status**: For a small subset of patients, determining HER2 amplification can inform eligibility for targeted HER2 therapies (e.g., trastuzumab), which can improve outcomes in HER2-positive CRC.\n\n5. **Tumor Gene Expression Profiling**: While not universally required, gene expression assays can provide additional insights into prognosis and potential treatment strategies.\n\nCollectively, these molecular assessments are essential to tailor therapy effectively, improve survival outcomes, and guide the management of advanced colorectal cancer in clinical practice."
    },
    "66301c47187cba990d000025":
    {
        "question": "What are the most common issues that need to be addressed in adults with Duchenne Muscular Dystrophy?",
        "llm_evidence": "Duchenne Muscular Dystrophy (DMD) is a progressive genetic disorder characterized by muscle degeneration and weakness primarily affecting boys. In adults with DMD, several common issues need to be addressed:\n\n1. **Progressive Muscle Weakness**: Adults often experience severe muscle wasting, leading to reduced mobility, frequent falls, and the need for assistance with daily activities. \n\n2. **Respiratory Complications**: As the disease progresses, respiratory muscles weaken, increasing the risk of respiratory infections and respiratory failure. Regular monitoring and ventilation support may be required.\n\n3. **Cardiac Issues**: Cardiomyopathy is common in DMD, necessitating regular cardiac evaluations to manage heart-related complications effectively.\n\n4. **Skeletal Complications**: Many adults develop scoliosis and joint contractures, which can greatly affect posture and mobility. Interventions such as physical therapy and surgical options might be needed.\n\n5. **Psychosocial Challenges**: Individuals often face mental health issues, including anxiety and depression, stemming from social isolation and the implications of living with a chronic condition. Counseling and support groups can be beneficial.\n\n6. **Nutritional Needs**: Maintaining a healthy diet is crucial as decreased mobility can lead to obesity, which exacerbates other health issues. Regular dietary assessments are important.\n\nOverall, a multidisciplinary approach involving physical therapy, respiratory care, cardiology, nutrition, and mental health support is essential to manage these issues effectively."
    },
    "6621510eb9f8b89d7e000008":
    {
        "question": "What histological features are described in colorectal tumors with BRAF mutation?",
        "llm_evidence": "Colorectal tumors with BRAF mutations, particularly the BRAF V600E mutation, exhibit distinct histological features that can aid in their identification and characterization. Key insights include:\n\n1. **Mucinous Histology**: A significant percentage of BRAF-mutated tumors demonstrate a mucinous subtype, characterized by abundant extracellular mucin production. This feature is commonly observed in colorectal cancer and is associated with poorer prognosis.\n\n2. **Poor Differentiation**: BRAF-mutated colorectal cancers often display poorly differentiated histology. These tumors tend to have high-grade features, including increased mitotic activity and necrosis.\n\n3. **Peritumoral Inflammation**: Histologically, there is often a prominent lymphocytic infiltrate surrounding BRAF-mutated tumors. This inflammation can indicate a complex immune response associated with tumor progression.\n\n4. **Crypt Distortion**: The architectural features of the tumor may show crypt distortion, which includes alterations in the normal structure of colorectal crypts, possibly leading to irregularly shaped glands and desmoplastic stroma.\n\n5. **Diminished Response to Therapy**: BRAF mutations are frequently associated with resistance to standard chemotherapeutic agents and targeted therapies, influencing histological features tied to tumor viability under treatment.\n\nUnderstanding these histological characteristics is crucial for pathologists and clinicians in the diagnosis and management of colorectal cancer, particularly for informing prognosis and therapeutic approaches."
    },
    "662e44e9187cba990d00000b":
    {
        "question": "Is vaccination against all arboviruses indicated for pregnant women?",
        "llm_evidence": "Vaccination against arboviruses for pregnant women is a nuanced topic that varies depending on the specific virus in question. For example, the Centers for Disease Control and Prevention (CDC) recommends the Zika virus vaccination for pregnant women, primarily due to the significant risks posed by Zika infection, which can lead to severe fetal complications such as microcephaly. \n\nHowever, vaccinations for other arboviruses, such as dengue or chikungunya, do not have the same level of recommendation, as evidential concerns regarding safety and efficacy during pregnancy remain unclear. The World Health Organization (WHO) provides guidance that emphasizes the importance of risk assessment: if a pregnant woman is in a region where a specific arbovirus is endemic or presents a high risk of transmission, vaccination may be indicated.\n\nIt is crucial to evaluate individual circumstances such as geographical exposure, the existence of potential complications, and the specific arbovirus in question when considering vaccination for pregnant women. Thus, while some vaccinations may be recommended, not all arboviruses have universally endorsed vaccines for pregnant women, making it essential to rely on health authority guidance and individual risk factors."
    },
    "662fc4b1187cba990d000016":
    {
        "question": "What are the mechanisms of action of regorafenib on tumor cells?",
        "llm_evidence": "Regorafenib is a multi-kinase inhibitor that exerts its anti-tumor effects through several key mechanisms of action:\n\n1. **Inhibition of Angiogenesis**: Regorafenib targets vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, as well as platelet-derived growth factor receptors (PDGFR). By inhibiting these pathways, it disrupts the formation of blood vessels that supply nutrients to tumors, thereby limiting tumor growth.\n\n2. **Direct Anti-Tumor Activity**: Regorafenib inhibits several kinases involved in tumor cell proliferation and survival, including the RAF kinase, which is crucial in the RAS/RAF/MEK/ERK signaling pathway. This inhibition leads to reduced oncogenic signaling, decreasing tumor cell proliferation.\n\n3. **Modulation of the Tumor Microenvironment**: By affecting the signaling pathways associated with the tumor microenvironment, regorafenib can alter the behavior of surrounding stromal cells, enhancing anti-tumor immune responses and potentially modifying the tumor's response to other therapies.\n\n4. **Induction of Apoptosis**: Regorafenib has been shown to promote apoptotic processes in tumor cells, increasing programmed cell death which is essential for reducing tumor mass.\n\nIn summary, regorafenib acts on tumor cells through inhibition of angiogenesis, direct anti-tumor activity by blocking key signaling pathways, influencing the tumor microenvironment, and inducing apoptosis, making it an effective treatment for various cancers, including colorectal cancer and gastrointestinal stromal tumors."
    },
    "661d5fe1eac11fad33000024":
    {
        "question": "What are the types of Polycystic Kidney Disease?",
        "llm_evidence": "Polycystic Kidney Disease (PKD) primarily includes two major types: Autosomal Dominant Polycystic Kidney Disease (ADPKD) and Autosomal Recessive Polycystic Kidney Disease (ARPKD).\n\n1. **Autosomal Dominant Polycystic Kidney Disease (ADPKD)**: This is the more common form, affecting approximately 1 in 400 to 1 in 1,000 individuals. ADPKD typically manifests in adulthood, and cysts can develop in both kidneys, leading to enlarged kidneys and potential kidney failure. It is often associated with mutations in the PKD1 or PKD2 genes.\n\n2. **Autosomal Recessive Polycystic Kidney Disease (ARPKD)**: This rarer form presents in infancy or early childhood, with an incidence of about 1 in 20,000 live births. Cysts in ARPKD are generally smaller and more concentrated in the collecting ducts of the kidneys. The condition is usually caused by mutations in the PKHD1 gene, and it may lead to significant complications at an early age.\n\nIn addition to these, there are also less common variations, including Mucinex Polycystic Kidney Disease and Von Hippel-Lindau Syndrome (associated with additional cysts and tumors), and nephronophthisis, which can also involve cyst formation. \n\nOverall, the classification of PKD highlights genetic implications, age of onset, and severity of the disease, aiding in diagnosis and management strategies."
    },
    "66214f52b9f8b89d7e000005":
    {
        "question": "Is tumor expression of Topoisomerase I a biomarker of response to irinotecan in colorectal cancer patients therapy?",
        "llm_evidence": "Tumor expression of Topoisomerase I (Top1) has been identified as a potential biomarker for predicting response to irinotecan therapy in colorectal cancer patients. Irinotecan, a topoisomerase I inhibitor, exerts its therapeutic effect by inducing DNA damage in cancer cells through the inhibition of this enzyme. Studies have shown that colorectal tumors with high levels of Top1 expression are more likely to respond favorably to irinotecan treatment, as these tumors are more susceptible to the drug's mechanism of action. Conversely, tumors with low Top1 expression have been associated with poorer outcomes and diminished sensitivity to irinotecan.\n\nMoreover, research has indicated that the effectiveness of irinotecan is influenced not just by the level of Top1 expression but also by the presence of genetic alterations in the cancer cells. Variations in the expression of related proteins and pathways can further modulate the therapeutic response. Therefore, assessment of Top1 expression in tumor biopsy samples could help in stratifying colorectal cancer patients for irinotecan therapy, potentially leading to more individualized treatment approaches and improved patient outcomes. This evidence supports the notion that Top1 expression is a significant biomarker for predicting the efficacy of irinotecan in colorectal cancer patients."
    },
    "662f401b187cba990d00000e":
    {
        "question": "Is Vitamin D deficiency associated with sepsis mortality?",
        "llm_evidence": "Vitamin D deficiency has been associated with increased mortality in patients with sepsis. Several studies have indicated that low levels of Vitamin D can impair the immune response, potentially leading to worse outcomes in critical illnesses such as sepsis. Vitamin D plays a crucial role in modulating the immune system, enhancing the function of immune cells, and reducing inflammation. \n\nResearch shows that patients with sepsis who have lower serum levels of Vitamin D experience higher rates of complications and mortality compared to those with sufficient levels. A systematic review and meta-analysis of various studies found a significant correlation between Vitamin D deficiency and higher mortality rates in sepsis patients. Additionally, interventions aimed at correcting Vitamin D deficiency have demonstrated potential in improving clinical outcomes in these patients. \n\nIn conclusion, evidence suggests that Vitamin D deficiency is associated with increased mortality in sepsis, highlighting the importance of monitoring and potentially supplementing Vitamin D in critically ill patients."
    },
    "66214b9cb9f8b89d7e000001":
    {
        "question": "Which countries have a higher incidence of colorectal cancer?",
        "llm_evidence": "Colorectal cancer incidence varies significantly across different regions, with the highest rates typically observed in developed countries. Notably, Australia, New Zealand, North America, and several countries in Western Europe, including the United Kingdom, Ireland, and Germany, have some of the highest reported incidences of colorectal cancer. \n\nKey insights include:\n\n1. **Lifestyle Factors**: Higher incidence rates in these regions are often linked to lifestyle factors such as diets high in red and processed meats, low physical activity, and obesity.\n   \n2. **Screening Programs**: Developed countries tend to have more advanced screening programs, which can lead to higher detection rates, thus influencing reported incidence figures.\n\n3. **Age Factor**: Colorectal cancer is more common in older populations, and countries with a higher median age may report increased incidence.\n\n4. **Geographical Variability**: Rates are generally lower in low- and middle-income countries, though rising due to Western dietary influences and urbanization. \n\n5. **Genetic Factors**: Certain populations may have genetic predispositions that contribute to higher cancer incidence.\n\nOverall, high incidence rates are primarily observed in economically developed regions, influenced by a combination of lifestyle, healthcare access, demographics, and genetic factors."
    },
    "66302978187cba990d000034":
    {
        "question": "What are the primary and secondary endpoints of Pamrevlumab?",
        "llm_evidence": "Pamrevlumab is a monoclonal antibody designed to inhibit connective tissue growth factor (CTGF), which is implicated in fibrosis and various fibrotic diseases, including idiopathic pulmonary fibrosis (IPF) and Duchenne muscular dystrophy (DMD). \n\n**Primary Endpoint:**\nThe primary endpoint in clinical trials for Pamrevlumab often focuses on measuring the impact on disease progression. For example, in DMD trials, the primary efficacy measure is typically the change in the North Star Ambulatory Assessment (NSAA) score or the time to loss of ambulation, whereas in IPF, it may involve the change in forced vital capacity (FVC) over time.\n\n**Secondary Endpoints:**\nSecondary endpoints may include assessments of safety and tolerability, quality of life measures, additional functional assessments (such as the 6-minute walk test), biomarkers of disease activity, and other measures of muscle function or respiratory status. These provide supportive data on the treatment’s overall impact and patient experience beyond the primary efficacy measures. \n\nBy measuring both primary and secondary endpoints, clinical trials aim to provide a comprehensive understanding of Pamrevlumab's therapeutic effects and its potential role in managing the target diseases."
    },
    "66099ac8fdcbea915f00001f":
    {
        "question": "What are the mechanisms of secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer treatment?",
        "llm_evidence": "Secondary resistance to anti-EGFR monoclonal antibodies in colorectal cancer is primarily driven by genetic and molecular alterations in tumor cells. Key mechanisms include:\n\n1. **KRAS Mutations**: Up to 30-40% of colorectal cancers harbor KRAS mutations, which confer resistance to anti-EGFR therapies. Mutations in codons 12 and 13 prevent upstream signaling inhibition by these antibodies, allowing continued tumor growth despite treatment.\n\n2. **BRAF Mutations**: Approximately 5-10% of colorectal cancers carry BRAF mutations, particularly BRAF V600E. These mutations activate downstream signaling pathways independently of EGFR, leading to resistance.\n\n3. **PIK3CA Mutations and PTEN Loss**: Alterations in the PIK3CA gene or loss of the tumor suppressor PTEN can activate the PI3K/AKT pathway, providing an alternative survival signal that diminishes the efficacy of EGFR blockade.\n\n4. **HER2 Amplification**: Some tumors may develop amplification of HER2, which can activate redundancy in signaling pathways that bypass EGFR inhibition.\n\n5. **Expression of Ligands**: Increased expression of ligands such as amphiregulin or epiregulin can lead to ligand-dependent activation of EGFR, contributing to treatment resistance.\n\nIn addition, phenotypic changes such as epithelial-mesenchymal transition (EMT) can alter the tumor microenvironment, further complicating the response to therapy. Understanding these mechanisms is essential for developing targeted strategies to overcome resistance in colorectal cancer treatments."
    },
    "661d19d5eac11fad33000007":
    {
        "question": "Can the neonatal Pediatric Sepsis Biomarker Risk Model (nPERSEVERE) accurately predict mortality in neonatal sepsis?",
        "llm_evidence": "The neonatal Pediatric Sepsis Biomarker Risk Model (nPERSEVERE) is designed to evaluate the risk of mortality in neonates with sepsis by integrating clinical and biomarker data. Key insights indicate that nPERSEVERE utilizes a combination of biomarkers, such as procalcitonin, C-reactive protein, and other inflammatory markers, alongside clinical parameters like age and vital signs to stratify risk levels. Research has shown that nPERSEVERE demonstrates high sensitivity and specificity in predicting outcomes, thereby aiding healthcare providers in identifying high-risk neonates who may require more intensive monitoring and intervention. Studies have highlighted its effectiveness in improving clinical decision-making and potentially reducing mortality rates in affected populations. Overall, evidence supports that nPERSEVERE can accurately predict mortality, making it a valuable tool in the management of neonatal sepsis."
    },
    "662fc0bc187cba990d000011":
    {
        "question": "Can calcium dietary supplementation reduce the risk of colorectal cancer?",
        "llm_evidence": "Calcium dietary supplementation has been associated with a potential reduction in the risk of colorectal cancer according to various epidemiological studies. Key insights include:\n\n1. **Mechanism of Action**: Calcium may help bind to potential carcinogens in the gut, reducing their absorption and limiting the proliferation of cancer cells. It also plays a role in cellular signaling and can promote normal cell differentiation.\n\n2. **Epidemiological Evidence**: Several large cohort studies and meta-analyses have shown that higher calcium intake correlates with a lower risk of colorectal cancer. Notably, a systematic review indicated that individuals with high calcium diets had a significantly reduced risk compared to those with lower intake.\n\n3. **Calcium Sources**: While supplementation can provide the necessary calcium, some studies suggest that calcium from dietary sources (like dairy products) may be more beneficial than from supplements alone due to additional nutrients that could also protect against cancer.\n\n4. **Nuances in Results**: The evidence is not entirely unanimous, as some studies have found no significant difference or varying results depending on population demographics or existing conditions such as vitamin D levels, which interact with calcium metabolism.\n\nOverall, while evidence supports a potential protective effect of calcium against colorectal cancer, factors such as the form of calcium intake and individual health conditions may influence outcomes. Thus, calcium supplementation might be beneficial, particularly if coupled with a balanced diet rich in other nutrients."
    },
    "66300ee7187cba990d00001c":
    {
        "question": "What is the prevalence of intellectual developmental disorders in Duchenne Muscular Dystrophy?",
        "llm_evidence": "Intellectual developmental disorders (IDD) are not uniformly prevalent in individuals with Duchenne Muscular Dystrophy (DMD), but studies indicate a notable association between DMD and cognitive impairments. Research suggests that approximately 30-50% of individuals with DMD may exhibit some form of intellectual disability, with a higher prevalence of learning difficulties and lower average IQ scores compared to the general population. These cognitive challenges are attributed to the primary genetic mutation affecting the dystrophin gene, which plays a crucial role in both muscle and brain development. Furthermore, environmental factors, such as the impact of physical disability on educational opportunities, can exacerbate these issues, leading to a significant portion of DMD patients also experiencing IDD. Understanding this correlation is vital for providing appropriate support and interventions for affected individuals."
    },
    "660999bffdcbea915f00001b":
    {
        "question": "Is treatment with acetyl salicylic acid indicated to prevent colorectal adenomas?",
        "llm_evidence": "Acetyl salicylic acid (ASA), commonly known as aspirin, has been studied for its potential role in the prevention of colorectal adenomas, which are precursors to colorectal cancer. Several epidemiological studies and clinical trials suggest that regular use of aspirin may reduce the incidence of colorectal adenomas, particularly in individuals with certain risk factors such as a family history of colorectal cancer or previous adenomatous polyps. The mechanisms proposed for this protective effect include aspirin's anti-inflammatory properties and its ability to inhibit cyclooxygenase (COX) enzymes, which play a role in tumorigenesis. \n\nHowever, the evidence is not definitive, and the current guidelines suggest that while aspirin may be considered for colorectal cancer prevention in some high-risk populations, it is not universally recommended for all patients due to potential side effects and the need for further research to establish optimal dosing and duration. Overall, treatment with acetyl salicylic acid may be indicated in a targeted manner rather than as a general preventive measure for colorectal adenomas."
    }
}